These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats. Klocek MS; Sassani JW; McLaughlin PJ; Zagon IS Exp Eye Res; 2009 Nov; 89(5):686-92. PubMed ID: 19576213 [TBL] [Abstract][Full Text] [Related]
5. Topical treatment with the opioid antagonist naltrexone facilitates closure of full-thickness wounds in diabetic rats. McLaughlin PJ; Pothering CA; Immonen JA; Zagon IS Exp Biol Med (Maywood); 2011 Oct; 236(10):1122-32. PubMed ID: 21917593 [TBL] [Abstract][Full Text] [Related]
6. Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats. Immonen JA; Zagon IS; Lewis GS; McLaughlin PJ Exp Biol Med (Maywood); 2013 Oct; 238(10):1127-35. PubMed ID: 23986225 [TBL] [Abstract][Full Text] [Related]
7. Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Zagon IS; Sassani JW; Carroll MA; McLaughlin PJ Brain Res Bull; 2010 Feb; 81(2-3):248-55. PubMed ID: 19853024 [TBL] [Abstract][Full Text] [Related]
8. Spontaneous episodic decreased tear secretion in rats is related to opioidergic signaling pathways. Zagon IS; Campbell AM; Sassani JW; McLaughlin PJ Invest Ophthalmol Vis Sci; 2012 May; 53(6):3234-40. PubMed ID: 22511629 [TBL] [Abstract][Full Text] [Related]
12. Ocular surface complications result from dysregulation of the OGF-OGFr signaling pathway in female diabetic rats. Purushothaman I; Zagon IS; Sassani JW; Mclaughlin PJ Exp Ther Med; 2021 Jul; 22(1):687. PubMed ID: 33986852 [TBL] [Abstract][Full Text] [Related]
13. Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Zagon IS; Sassani JW; McLaughlin PJ Cornea; 2006 Aug; 25(7):821-9. PubMed ID: 17068460 [TBL] [Abstract][Full Text] [Related]
14. Blockade of OGFr delays the onset and reduces the severity of diabetic ocular surface complications. Zagon IS; Sassani JW; Purushothaman I; McLaughlin PJ Exp Biol Med (Maywood); 2021 Mar; 246(5):629-636. PubMed ID: 33203224 [TBL] [Abstract][Full Text] [Related]
15. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease. Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587 [TBL] [Abstract][Full Text] [Related]
16. Preservation of tear film integrity and inhibition of corneal injury by dexamethasone in a rabbit model of lacrimal gland inflammation-induced dry eye. Nagelhout TJ; Gamache DA; Roberts L; Brady MT; Yanni JM J Ocul Pharmacol Ther; 2005 Apr; 21(2):139-48. PubMed ID: 15857280 [TBL] [Abstract][Full Text] [Related]
17. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review. McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562 [TBL] [Abstract][Full Text] [Related]
18. A distinct cytokines profile in tear film of dry eye disease (DED) patients with HIV infection. Agrawal R; Balne PK; Veerappan A; Au VB; Lee B; Loo E; Ghosh A; Tong L; Teoh SC; Connolly J; Tan P Cytokine; 2016 Dec; 88():77-84. PubMed ID: 27585367 [TBL] [Abstract][Full Text] [Related]
19. Effect of once daily topical 0.3% naltrexone on tear parameters and corneal sensitivity in dogs with uncontrolled keratoconjunctivitis sicca: a double-masked randomized placebo-controlled clinical trial. Chen T; Powell CC Vet Ophthalmol; 2015 Nov; 18(6):497-501. PubMed ID: 25675975 [TBL] [Abstract][Full Text] [Related]
20. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Jain P; Li R; Lama T; Saragovi HU; Cumberlidge G; Meerovitch K Exp Eye Res; 2011 Oct; 93(4):503-12. PubMed ID: 21726552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]